Renewable Energy Group Wants Investors' Respect

Renewable Energy Group is jumping into biobased chemicals with its newly acquired industrial biotech platform. Will it finally gain some respect from investors?

Feb 18, 2014 at 11:42AM

The level of uncertainty facing Renewable Energy Group (NASDAQ:REGI), the nation's largest biodiesel producer, reached a heightened level after the blender's tax credit expired on the last day of 2013. The credit was overwhelmingly responsible for the company's profitable operations last year, which has many fearing the worst for margins this year.

It is possible for the credit to be reinstated retroactively in the future (as it was for 2012), but the U.S. Environmental Protection Agency is facing larger problems as it nears a final decision on the future of the Renewable Fuel Standard. Besides, investors can't feel completely comfortable being at the mercy of the EPA every 12 months.

While Renewable Energy Group has invested heavily in efficiency and feedstock flexibility to combat volatile input costs -- and those investments will certainly widen margins -- biobased diesel fuels, whether traditional biodiesel or renewable diesel, will remain low-margin products. That's just reality. It's also a big reason why Wall Street is keeping its distance from the company. However, I think it's evident that the long term business and technology strategies are being overlooked by Mr. Market. Can the recent acquisition of industrial biotech company LS9 finally buy Renewable Energy Group some respect? And what does it mean for your window to invest?

Buy-o-tech
Management understands that while biobased diesel fuels are important for the nation's transportation sector and can be valuable products if commercialized intelligently, it just isn't wise to strap your business to the EPA year-after-year. That's why the executive team started off 2014 by diversifying its core biodiesel business with the addition of REG Life Sciences and the acquisition of LS9, an industrial biotech company developing a synthetic biology platform for producing commodity and specialty chemicals via fermentation. The opportunities are astounding.

Reglifesciences

Investors shouldn't brush off the acquisition. Sure, it may take several years to fully commercialize the technology platform and consistently and reliably produce industrial quantities of products, but Renewable Energy Group can utilize existing operations to fund development. It can also leverage its extensive supply network for sourcing feedstock and take advantage of its national distribution network to sell products.

Reglifesciences

Moving into industrial biotech presents several key opportunities to Renewable Energy Group and its shareholders.

  1. Spreads risk and growth potential across multiple industries and products.
  2. Provides access to high-value, high margin products.
  3. Averts disaster from regulatory uncertainty.

Will Mr. Market take notice of the growth potential?

Buying respect?
The stigma of biofuels has muted investor enthusiasm for Renewable Energy Group despite the continued creation of shareholder value. Let's evaluate the company's balance sheet with the following chart, which displays percentage change in shareholders' equity and share count as of the end of the third quarter of 2013 relative to the company's IPO.

REGI Chart

REGI data by YCharts

While share count had increased by 24%, shareholders' equity had risen 78% since its IPO -- more than offsetting the dilution. It's important to note two things here: (1) share offerings have only occurred during acquisitions of companies and biodiesel facilities and (2) value creation has occurred during times of regulatory uncertainty (no blender's tax credit) and certainty (blender's tax credit available). Yet, despite the growth in shareholders' equity, share price has only risen 12% since the company's IPO.

Perhaps an easier way to digest the mix of shareholders' equity gains and share offerings is to evaluate book value, which accounts for dilution.

Date

Book Value

Percent Change

January 27, 2012 (IPO)

$9.37 per share

---

September 30, 2013 (End of 3Q13)

$15.89 per share

69.6%

Source: SEC filings

Does that make any sense to you? Now, of course, by the time full-year 2013 results are announced the total share count will have increased to roughly 40.7 million, or an increase of 42% since the company's IPO in early 2012. But even assuming shareholders' equity remains constant -- bucking the trend of quarterly increases since the IPO -- book value would still sit at $13.94 per share. I think the numbers speak for themselves.

Foolish bottom line
Why did Renewable Energy Group turn to biotech? It's really quite simple. The bioeconomy (biopharmaceuticals, biotech crops, and industrial biotech) is one of the fastest growing parts of the American economy. The way I see it (and what the numbers seem to demonstrate), the annual volatility of the nation's biofuel initiatives and the market's distaste for biofuel companies in general are creating an enormously valuable long-term opportunity for investors when accounting for the company's new industrial biotech platform.

Biofuels aren't for everyone
Don't want to expose your portfolio to the volatile and politically dizzying biofuels space? That's fine, but don't shun the energy sector! Record oil and natural gas production is revolutionizing the United States' energy position. Finding the right plays while historic amounts of capital expenditures are flooding the industry will pad your investment nest egg. For this reason, the Motley Fool is offering a comprehensive look at three energy companies set to soar during this transformation in the energy industry. To find out which three companies are spreading their wings, check out the special free report, "3 Stocks for the American Energy Bonanza." Don't miss out on this timely opportunity; click here to access your report -- it's absolutely free. 

Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, CAPS pageprevious writing for The Motley Fool, or his work for the SynBioBeta to keep up with developments in the synthetic biology industry.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers